Strategy acquired 267 more Bitcoin, increasing its total holdings to a record 848,517 BTC, about 4.04% of Bitcoin's max supply. Alongside, it repurchased $193 million of its STRC preferred stock and raised its digital credit securities repurchase authorization from $2 billion to $3 billion. The company reported $5.3 billion in dollar assets, down from $5.5 billion the previous week, reflecting capital allocation between Bitcoin purchases and preferred stock buybacks. These moves highlight Strategy's dual focus on growing its Bitcoin treasury and managing its financing structure through preferred stock repurchases.
Strategy's recent Bitcoin and STRC buyback moves provide context for readers following cryptocurrency markets. As of Oct 19, 2026 19:21 WIB, among 50 major cryptocurrencies on Pluang, 23 rose and 25 fell. Notably, SAND fell 2.80% with a typical hold time of 123 days and a 65% buy order activity, contrasting with UNI which rose 2.26% but saw 86% sell orders and a shorter hold time of 65 days, while FIL declined 2.65% with 61% buy orders and a 100-day hold time.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
